• Lexaria’s DehydraTECH(TM) technology has 28 granted patents, with many more patents pending worldwide
• DehydraTECH(TM) uses a patented formulation and dehydration process method to change how the body detects and absorbs drugs
• Lexaria is focusing on three main areas: CBD for hypertension, oral nicotine to replace vaping and smoking, and CBD potentially for diabetes and seizures
• Lexaria is conducting early work to support its FDA-registered IND program to investigate DehydraTECH(TM)-processed CBD for hypertension

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, is increasing the bioavailability and improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through its patented proprietary technology, DehydraTECH(TM). DehydraTECH is applied to multiple ingestible product formats, such as tablets, capsules, oral suspensions, mouth melts, and others, with opportunities for success in cannabinoids, nicotine, antivirals, and other APIs. To date, Lexaria has 28 granted patents, with many more patents pending worldwide.

Lexaria’s DehydraTECH uses a patented formulation and dehydration processing method that changes how the body detects and absorbs drugs. The DehydraTECH process is beneficial to the end user because it speeds up onset, increases bioavailability, improves drug potency, eliminates the need for sugar-filled edibles, lowers dosage, and lowers administration costs.

In 2023, the company is focused on three main areas: cannabidiol (“CBD”) for hypertension, oral nicotine to replace vaping and smoking, and other applications for DehydraTECH-CBD such as diabetes and seizures. Lexaria has yielded several studies that have proven beneficial for its research and development efforts, including five human clinical trials completed involving DehydraTECH-CBD.

HYPER-H21-4 consisted of male and female volunteers between the ages of 40-70 with documented or measured elevated blood pressure. Participants received DehydraTECH-CBD every day for a 5-week duration, with doses escalating between 225 mg/day to 450 mg/day over the course of the study, adjusted relative to body weight. Some participants were already using the industry standard of care for hypertension, allowing Lexaria to study the efficacy and safety of DehydraTECH-CBD with and without other hypertension treatments. The extended duration of the study allowed Lexaria to gather critical data to evaluate the potential for long-term health benefits of its DehydraTECH-CBD formulation.

“Given that these were the primary objectives of the study, it is accurate to say that HYPER-H21-4 was a success,” Lexaria CEO Chris Bunka said in his annual letter to shareholders recently (https://ibn.fm/2Ewzv). “In addition, a series of secondary study objective evaluations, as previously announced, are in progress, and these findings will be released in due course if any of them are notable.”

Lexaria expects to launch its FDA-registered IND program to investigate DehydraTECH-CBD for hypertension formally. The program is a large undertaking, one that will dominate the second half of 2023 and beyond – the company expects to conduct fewer additional smaller studies than they have in years past due to the focus required for this study. Preparatory work for this Phase 1b study is well underway.

“We continue to enjoy more successes than failures. We’re hopeful that our commercial endeavors might obviate any need to raise capital via equity issuance at current market levels, and our tight fiscal controls have greatly assisted in that pursuit,” Bunka also said. He added that the company will explore various commercial arrangements in 2023 in order to increase cash flow, while also continuing efforts to build and enhance its client base.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products
• The company’s alpaca-derived nanosized antibodies (“NanoAbs”) exhibit superior valuable competitive advantages over commercially available monoclonal antibodies (“mAbs”), including better specificity and affinity to the target, hyper-thermostability, and potential for more effective and convenient routes of administration
• Preclinical in vivo data have shown its lead drug candidate, the inhaled anti-SARS-CoV-2 NanoAb, led to a significantly shorter and milder illness, virtually eliminated the virus from the lungs, and effectively prevented illness when administered prophylactically
• BiondVax aims to fill the void in COVID-19 therapeutics and is forging ahead with clinical efforts needed to support this goal

With the COVID-19 disease now in its fourth year, questions abound about how the pandemic will be felt in 2023. The complex interaction of the vaccinations, available therapeutic drugs, newly emerging COVID-19 drugs, and natural immunity complicates the process of determining crucial parameters that can be used to make projections surrounding disease severity and extent of the spread of the SARS-CoV-2 virus (https://ibn.fm/6f3Ng). To further compound the issue, newly emerging Omicron subvariants have rendered previously effective and approved monoclonal antibody drugs virtually ineffective, leading to the Food and Drug Administration (“FDA”)’s withdrawal of their authorization. Plus, most observers agree that the progression and evolution of the variants remain largely unpredictable three years on.

If the unpredictability and daily developments have taught us anything, it is the need for improved therapeutics. Such a therapeutic should be able to deal with both the existing and new subvariants and variants of the virus. Jerusalem-based biotechnology company, BiondVax Pharmaceuticals (NASDAQ: BVXV), and its strategic collaborators, the Max Planck Institute for Multidisciplinary Science (“MPI”) and the University Medical Center Göttingen (“UMG”), may have cracked the code, with their VHH antibodies or nanosized antibodies (“NanoAbs”) as the cryptographic key.

In addition to COVID-19, BiondVax and its collaborators aim to target indications with large unmet medical needs and growing market sizes like psoriasis, asthma, macular degeneration, and psoriatic arthritis, all diseases with known and validated antibody drug targets. According to the company, this will help shorten development timelines and lower risk. Initially, BiondVax is concentrating on COVID-19, having developed an inhaled anti-SARS-CoV-2 NanoAb candidate with potentially superior therapeutic capabilities against COVID-19.

In particular, BiondVax’s NanoAb candidate has exhibited superior affinity to its SARS-CoV-2 target, neutralizing the virus, in vitro, at drug concentrations about 100x lower than those required by previously commercially available monoclonal antibodies (“mAbs”) (https://ibn.fm/7YmGD). In a subsequent ongoing preclinical in vivo study in a standard animal model,  data has shown that the anti-COVID-19 therapy virtually eliminated the virus from the lungs (https://ibn.fm/rRM6H) and prevented illness when administered prophylactically (https://ibn.fm/jQ4Vg). It also showed that the anti-SARS-CoV-2 NanoAb led to a significantly shorter and milder illness (https://ibn.fm/k2Kqy).

Generally, NanoAbs exhibit a number of competitive advantages over mAbs. Firstly, they demonstrate superior specificity and binding affinity to the target, which can increase safety and efficacy at lower doses, allowing production at a lower cost. Secondly, they exhibit hyper-thermostability at high temperatures, potentially enabling longer shelf life and voiding the need for enhanced cold chain storage and transport.

Furthermore, their small size also enables more effective and convenient routes of administration, including inhalation. (For perspective, current mAb therapies are generally administered intravenously in a hospital setting,) And while inhaled therapeutics can be difficult to develop, BiondVax is working with industry-leading companies and organizations to develop a cost-effective, convenient, and reliable drug-device product.

According to the company, NanoAbs exhibit the potential to capture significant market share as biobetters; biobetters target the same epitope as commercially available antibodies but have improved properties. BiondVax is particularly encouraged by the high demand for COVID-19 therapeutics, demonstrated partly by the ~$18.9 billion in sales reported by Pfizer Inc. (NYSE: PFE) in 2022 for its Paxlovid drug (https://ibn.fm/iEWKn), even with the drug’s limitations of use because of serious cross-reactions with other medications and multiple other comorbidity contraindications.

Another source of encouragement is that the COVID-19 NanoAb candidate has demonstrated strong neutralization of all Omicron variants of concern (“VoC”), showing superiority over the now-deauthorized COVID-19 mAbs, which are insufficiently efficacious against Omicron and its subvariants. With the preclinical in vivo data proving highly encouraging, BiondVax plans to undertake its first-in-human clinical trial in 2023.

BiondVax Pharmaceuticals is out to prove that great things come in Nano-sized molecules and is laser focused on developing, manufacturing, and commercializing NanoAb immunotherapeutic products for the treatment of infectious diseases and large market disorders.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• The International Energy Agency predicts global energy subsidies topped record high of $1 trillion in 2022, contributing to incorrect price signaling, market distortion, rising government spending, discourage renewable energy adoption
• GeoSolar develops whole home renewable energy solutions that can help insulate building owners from price shocks, contribute to energy independence
• SmartGreen(TM) Home system comprises geothermal ground loops, photovoltaic solar panels, integrated air ducts and floor loops, CERV(R) air filtration, upgrades to insulation, lighting systems, and windows
• GeoSolar plans to market SmartGreen(TM) to over 120 million homes across U.S., system can be integrated into both newly built and existing residences and commercial buildings

The International Energy Agency (“IEA”) predicts that global energy subsidies topped a record high of $1 trillion in 2022 (https://ibn.fm/mW3I9). The amount doubled from the previous year, indicating that energy markets are volatile and further contributing to global price instability. GeoSolar Technologies (“GST”), a Colorado-based climate technology company, offers SmartGreen(TM) – a whole-home renewable energy system that can help protect homeowners from price volatility while offering energy independence.

The IEA strongly supports eliminating or minimizing fossil fuel subsidies due to their adverse effects on energy markets. According to the agency, subsidies cause incorrect price signaling, market distortion, and rising government spending while discouraging renewable energy adoption. Further, the agency believes that the expansion of subsidies additionally challenges the political landscape, with Russia emerging as the most significant contributor, followed by Iran and China.

GeoSolar’s innovative technology presents a multi-pronged solution that can insulate homeowners from energy instability caused by subsidies while reducing dependence on fossil fuels. The company’s SmartGreen(TM) Home system leverages renewable energy systems and efficiency improvements to dramatically lower or even eliminate utility bills. Geothermal ground loops and photovoltaic solar panels tap into the energy of the sun and earth to generate enough power to run appliances and vehicles. Integrated air ducts and floor loops maintain an optimal temperature in any climate, and upgrades to insulation, lighting systems, and windows improve efficiency. In addition, CERV(R) air filtration provides healthy and safe indoor air quality while filtering out pollutants.

GeoSolar aims to make SmartGreen(TM) accessible and affordable through various financing options, tax deductions, and utility incentives. The company plans to market the system to over 120 million homes across the United States with options for newly built and existing residences and commercial buildings. GeoSolar is additionally conducting a Reg A+ capital raise that allows anyone to invest in GeoSolar Technologies Inc. and the SmartGreen(TM) system.

For information on GeoSolar’s Regulation A+ capital raise, visit https://www.manhattanstreetcapital.com/geosolar-technologies-inc.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Prime Harvest recently revealed that the company’s Reg A+ equity offering has been greenlighted by the SEC
• The primary share offering will see the company market up to 10 million shares to investors at a price of $4.20 each, with estimated gross proceeds of $42 million
• The company has said that net proceeds will be destined towards the acquisition of licensed assets, continued expansion of their delivery network and general corporate purposes

Prime Harvest, a technology-focused, full-service cannabis company based in San Diego, recently announced the qualification of its equity offering under the SEC’s Regulation A+. The offering, which has officially been qualified by the U.S. Security Exchange Commission (“SEC”) as of Jan. 25, 2023, will provide the company with authorization to commence marketing its upcoming equity placement to both, accredited and non-accredited investors via its online platform, www.Weed4ThePeople.com (https://ibn.fm/yx1PM).

Prime Harvest plans to raise gross proceeds of up to $42 million through its primary share issuance, a corporate action which will see the company offer up to 10,000,000 shares of common stock for sale at an initial public offer price of $4.20 per share. The company has announced that gross proceeds from the equity raising will be destined towards the acquisition of licensed assets, the development of Prime Harvest’s direct-to-consumer application, expansion of the company’s state-wide delivery capabilities, as well as general corporate purposes.

Dating back to the company’s change in corporate strategy in 2019, a move which saw Prime Harvest transition from its origins as one of San Diego County’s founding brick and mortar cannabis outlets towards a tech-focused retailer through its Jaxx Cannabis flagship retail and delivery platform, the company has seen its prospects rise to new highs. Boasting over 60+ brand partners, Prime Harvest has seen its revenues swell by upwards of 784% between 2019-2021, a function of the company seeing its unique customer numbers rise by over 212% during that interim, with the average consumer expending $75 on average per purchase.

More recently, Prime Harvest and its retail brand, Jaxx Cannabis, have taken the sale of cannabis to new technological heights through the creation and development of the Jaxx Delivery Mobile App. A reliable, sophisticated and easy to use platform, the Jaxx Delivery App aims to expand the company’s footprint to encompass much of California’s legal market – a bold and arduous move given the rising demand from previously unexploited submarkets within the Golden State.

Prime Harvest’s actions come at a pivotal time for the US cannabis market, with over 33 US states as well as the District of Columbia currently sanctioning the legal use of some form of cannabis. Consequently, the legal cannabis industry has rapidly become one of the fastest growing sectors of the US economy, with a recent study noting that the industry accounted for 250,000 jobs as of 2020 and would likely grow to a market size of $24.1 billion by 2025 (from $6.6 billion in 2016). One study in the meantime has opined that California alone could account for a remarkable $25 billion of a projected $50 billion nationwide market by 2026.

Despite predictions on market growth being wildly divergent on the back of varying levels of optimism surrounding the industry’s development prospects, Prime Harvest has sought to pre-emptively ensure that they will be able to capitalize on the sector’s ongoing evolution through its upcoming capital raising exercise as well as its market leading retail offer via Jaxx Cannabis.

For more information, visit the company’s website at www.PrimeHarvestInc.com.

NOTE TO INVESTORS: The latest news and updates relating to Prime Harvest are available in the company’s newsroom at https://ibn.fm/PRIME

• D-Wave’s Leap(TM) cloud service will soon be available in 39 countries, including Israel, and will be accessible directly from D-Wave or AWS Marketplace
• The company is also expanding its feature selection offering, a fundamental part of machine learning, which has already shown promising results among customers in areas such as fraud detection and TV advertising optimization
• D-Wave also shared an update to its balance sheet including $20 million raised through ELOC

D-Wave Quantum (NYSE: QBTS), a leader in quantum computing systems, software, and services is transforming multiple industries as the world’s first commercial supplier of quantum computing solutions. D-Wave recently announced a series of product and business updates demonstrating the company’s continued progress and the momentum of its leadership in driving quantum commercialization, including a broad feature selection initiative to accelerate artificial intelligence/machine learning (AI/ML) workflows and expansion of its Leap quantum cloud service to Israel (https://ibn.fm/rnUjV).

As companies across multiple industry sectors increasingly adopt AI technology, feature selection has emerged as a key building block to help with machine learning workflows. D-Wave plans to build out its feature selection market offerings, which will span the company’s quantum hybrid solvers and professional services. It will apply its systems and services to address the growing need for finding efficient solutions to the most difficult business problems.

Feature selection is the problem of determining a small set of the most representative characteristics to improve model training and performance in machine learning. It is a critical component of machine learning and yet represents a problem that is difficult to solve through classical computers. D-Wave’s feature selection offering focuses on using quantum hybrid approaches to optimize feature selection in AI/ML model training and prediction. Based on promising work with D-Wave’s customers, the feature selection offering has demonstrated early results in areas like fraud detection and TV commercial advertising optimization. Customers can access D-Wave’s feature selection offering directly from D-Wave or AWS Marketplace (https://ibn.fm/it9Hw).

In addition to feature selection, the company also announced that the Leap quantum cloud service would soon have availability in Israel. This will allow businesses, developers, and researchers to access D-Wave’s Advantage(TM) quantum computer, hybrid quantum/classical solvers, and the integrated developer environment (“IDE”) in real-time via Leap to drive the development of business-critical, in-production hybrid applications. On March 8th, 2023, Leap will be available in 39 countries worldwide, including Israel, and will be accessible directly from D-Wave or AWS Marketplace.

“D-Wave is rapidly accelerating the commercialization of quantum computing. We’re taking a number of steps to help our customers expeditiously unlock the power of quantum computing for the enterprise today, including expanding our feature selection offerings to help solve key AI/ML workstreams, enabling access to our Advantage system in new countries, including Israel, and adopting new processes and compliance measures to reinforce our commercial-readiness,” said Alan Baratz, CEO of D-Wave.

In addition, Baratz said the company is building upon its cash position by pursuing a variety of financing options to increase access to capital and to execute on the growth opportunities ahead. Since late October 2022, D-Wave has raised approximately $20 million under the previously announced $150 million Equity Line of Credit (“ELOC”) with Lincoln Park Capital. The ELOC has been an efficient source of capital for the company during this period. The company may seek to access additional capital under the ELOC when D-Wave determines appropriate as an ongoing mechanism to fund its operations.

Baratz also said the company is expected to finance cash needs through public and/or private equity (including sales pursuant to the ELOC) and/or debt financings or other capital sources, including strategic partnerships. D-Wave reported that its current cash balance has improved since its last report in September 2022.

For more information, visit the company’s website at www.DWaveQuantum.com.

NOTE TO INVESTORS: The latest news and updates relating to QBTS are available in the company’s newsroom at https://ibn.fm/QBTS

Forward-Looking Statements

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which statements are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. We caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, which are subject to a number of risks. Forward-looking statements in this article include, but are not limited to, statements regarding D-Wave’s plans to build out its feature selection market offerings, the expansion of the Leap quantum cloud service to Israel, and its pursuit of, and the potential success and impact of, various financing options. We cannot assure you that the forward-looking statements in this article will prove to be accurate. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management’s control, including general economic conditions and other risks; customer acceptance of our products and services; and the uncertainties and factors set forth in the sections entitled “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in the registration statement on Form S-1 filed by the Company with the SEC on February 13, 2023, as well as factors associated with companies, such as D-Wave, that are engaged in the business of quantum computing, including anticipated trends, growth rates, and challenges in those businesses and in the markets in which they operate; the outcome of any legal proceedings that may be instituted against us; risks related to the performance of our business and the timing of expected business or financial milestones; unanticipated technological or project development challenges, including with respect to the cost and or timing thereof; the performance of our products; the effects of competition on our business; the risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; the risk that we may never achieve or sustain profitability; the risk that we are unable to secure or protect our intellectual property; volatility in the price of our securities; the risk that our securities will not maintain the listing on the NYSE; changes in applicable laws and regulations; the effect of pandemics, geopolitical events, natural disasters, wars, or terrorist acts on our business or the economy in general; and the impact of inflation. Furthermore, if the forward-looking statements contained in this article prove to be inaccurate, the inaccuracy may be material. In addition, you are cautioned that past performance may not be indicative of future results. In light of the significant uncertainties in these forward-looking statements, you should not place undue reliance on these statements in making an investment decision or regard these statements as a representation or warranty by any person we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking statements in this article represent our views as of the date of this article. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this article.

• Corporate rebrand, launch designed to reflect the company’s global mission
• CISO Global was founded to bring cybersecurity professionals together on a global basis
• Organizations spent around $150 billion in 2021 on cybersecurity, growing by 12.4% annually and creating a significant opportunity

Cerberus Cyber Sentinel (NASDAQ: CISO) is starting off the new year with a new name, brand and logo (https://ibn.fm/Mxai7). The company, which has established itself as a leading cybersecurity and compliance provider, has announced plans for a corporate rebrand and launch designed to reflect the company’s global mission.

“At the heart of the rebranding is a change of the company name to CISO Global Inc. and an update to [our] corporate logo,” the company stated in the announcement. “The new brand identity marks another major milestone in the evolution of Cerberus Sentinel, embodies the enthusiasm of its employees, and is indicative of the company’s movement forward.”

In the past few years, the company has experienced impressive growth on three continents: North America, South America and Europe. With the current upward trend and future growth in bmind, company officials decided that creating a strong parent brand in the marketplace was essential while ensuring the new identity matches the global enterprise the company is actively becoming.

“CISO Global was founded to bring cybersecurity professionals together on a global scale,” said David Jemmett, CEO and founder of CISO Global. “We have assembled a world-class leadership team, and we have successfully brought together 16 organizations globally. It is time for our name to reflect who we are as an organization.”

Cybersecurity is becoming increasingly important in today’s digital world and is a top priority for savvy businesses. A recent McKinsey & Company report noted that cyberattacks are proliferating, causing trillions of dollars of damage every year:

“As the digital economy grows, digital crime grows with it,” the report stated. “Soaring numbers of online and mobile interactions are creating millions of attack opportunities. Many lead to data breaches that threaten both people and businesses. At the current rate of growth, damage from cyberattacks will amount to about $10.5 trillion annually by 2025 — a 300% increase from 2015 levels. In the face of this cyber onslaught, organizations around the world spent around $150 billion in 2021 on cybersecurity, growing by 12.4% annually.”

That growing demand can’t be ignored. “The distributed nature of cybersecurity requires global capabilities to properly address the demands and complexities of today’s business environment,” said CISO Global President and Chief Information Security Officer Ashley Devoto. “We are on a mission to demystify and accelerate our clients’ journey to cyber resilience, empowering organizations to securely grow, operate and innovate.”

Devoto pointed out that the company’s M&A growth strategy considers both the growth opportunity and the cyber talent shortfall. “That, combined with growing cybersecurity compliance complexities and requirements, including those by the U.S. Securities and Exchange Commission and the U.S. Department of Defense Cybersecurity Maturity Model Certification (“CMMC”), means that businesses are facing mounting pressure often beyond their capacity to manage internally,” she concluded.

CISO Global has a presence in North America, South America, and the United Kingdom. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services, and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations against continuing and emerging security threats and to meet compliance obligations.

For more information, visit the company’s website at www.CerberusSentinel.com.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

The Alternatives Products Expo, organized by ZJ Events is being held in Fort Lauderdale March 3-5, 2023. Exhibitors can showcase their products and market their innovative ideas in front of a large audience of potential investors. This premier counterculture show will feature a diverse range of products including CBD, DELTA-8, Nicotine Alternatives, Kratom, Extracts, Functional Beverages, and more.

The Alternative Products Expo will offer participants a unique experience, offering access to new products and free samples available only at the show, as exhibitors pitch their services, products, and ideas to expand the attendees’ knowledge base.

All mainstream products have an alternative product option, and this market is expected to produce an increasingly promising outcome as it develops. The Alternative Products Expo represents a tremendous avenue to establish networking ties and connect with a wider counterculture audience. The alternative product category includes a broad spectrum of herbal products, mood enhancers, cannabis derivatives, vape products, energy boosts, and dietary supplements, to name a few.

The event is curated for the alternative products industry based upon years of the ZJ Events organizers experience. The event team complies with relevant information and brings together like-minded businesses and professionals on a common forum for lucrative networking and business collaborations.

More than 100+ exhibitors, 1000s of registered buyers, notable brands, media partners, and influential marketing partners, are expected to attend the show. The Alternative Products Expo unites the finest executives, companies, and industry professionals, for a much-awaited event.

Jason Monti, Co-Founder of the event stated that, along with the iconic energy and vibes that the show brings, they will focus on the business aspect of the event. As Florida is a business hub for alternative products, businesses in this spectrum can leverage the event platform to network and expand their horizons. As changes in regulations are underway, this is a turning point for the alternatives products industry where more businesses can seize the opportunities offered.

The organizers are offering Alt Pro Buck, an option for industry buyers to increase their purchasing power. This new Benefit is exclusive to industry buyers and is available on the show’s registration website.

Join us at Alternative Products Expo Fort Lauderdale 2023! For a special gift, use the code FTL or CLICK HERE.

For more information, please visit https://ibn.fm/uNovL.

• Bed and bath lifestyle brand Coyuchi Inc. delivers comfortable and renowned luxury textile all-organic products that are renowned for their look, feel, and luxury appeal
• The company’s sustainable living standard includes a traceable supply chain and a 2nd Home Take Back(TM) platform that gives new life to returned items
• An important element of Coyuchi’s popularity is the company’s sense and incorporation of color trends, providing products with dye-free hues that evince a range of moods and create the ultimate in natural appeal
• The company’s color choices and design details are inspired by Coyuchi’s connection to the relaxed lifestyle of the northern California coastline

Ever since Sir Isaac Newton established the first color wheel and defined the relationship of light to the spectrum’s color divisions over 350 years ago (https://ibn.fm/HbXSf), the hues revealed by prisms have been subjected to study by the scientific community.

In the modern era, architects, clothiers as well as bed and bath fashion retailers, utilize developments in the science of color to guide their work and its influence on human emotion. Luxury bed, bath and apparel organic product innovator Coyuchi displays a clear interest in color trends with products designed alternately to warm or cool their use space.

Coyuchi’s earth-sustaining, comfortable products range from pajama pants to pillow cases and shower curtains, each item created with 100 percent organic cotton fibers. As an example, the company’s bed linens come in cool colors designed to provide restorative therapeutic qualities, warm colors designed to provide a sunny taste of modernity, coastal greens that reflective simple, natural elements and the company’s namesake cotton brand that offers a dye-free taste of materials at their most basic.

“Our design inspiration is the northern California coast – the colors, the design details and the attention to how every product feels. I grew up on the California coast and there’s a relaxed lifestyle that we’d like everyone to feel; that’s what we’re creating for our customers, the relaxed feel of life by the coast,” CEO Eileen Mockus stated (https://ibn.fm/rwIuK).

The company’s name, Coyuchi, is derived from the Aztec language Nahuatl and refers to the color of coyote fur — a dusty, bleached brown that is also that basic color of organic cotton (https://ibn.fm/NlYe3).

Scientific research into the psychology of people’s moods has shown that certain colors can evoke specific feelings. The different extremes of the light spectrum have been associated with physiological changes, including increased blood pressure, increased metabolism, and eyestrain.

A recent study found people connect blues and whites with relief, while orange and yellow hues evoke joy and greens give rise to feelings of contentment, for example (https://ibn.fm/9TfgK). White-colored pills are associated with greater pain relief, while red pills are associated with stimulant properties. And black-uniformed players are more likely to receive penalties in competitive sporting events. Even colors in the same warm or cool families can spark different reactions, depending on the shade (https://ibn.fm/AYOvx).

Whatever the color, Coyuchi’s products provide environmentally conscious homes with home textiles that are soft and luxurious and built to last, and colors that display both a sensitivity and respect for nature. The company’s focus on earth stewardship comes with a traceable supply chain, and Coyuchi’s “circular initiative” was responsible for establishing the company’s 2nd Home Take Back(TM) platform in which linens returned to Coyuchi are cleaned by partners at the Renewal Workshop, checked for flaws and repaired if necessary to be as good as new for the 2nd Home program lineup.

If the material is too damaged to be used again, it is “aggregated” for recycling, according to the company.

For more information, visit the company’s website at www.Coyuchi.com.

NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• Specialized mortgage lender REZYFi Inc. is strategically serving the needs of consumers and cannabis-related businesses through an alternative loan financing approach
• The company’s alternative mortgage financing strategy relies on real estate and other assets of the borrowers to secure loans for clients whose financial history or legal revenue base may make them unattractive borrowers for traditional banks
• The cannabis industry has long struggled to secure loans despite its cash-intensive operations because of the federal government’s choice not to recognize the industry
• REZYFi’s strengths as a lender include efficient operations supported by skilled staffing with years of expertise in the industry, , and a supportive network of independent brokers and loan officers

The emergence of the alternative mortgage loan financing market in recent years has made it simpler and easier for consumers to get a mortgage, even with what might be regarded as a past history of poor loan risk decisions. Nevertheless, special challenges remain for cannabis operators.

Florida-based REZYFi is a mortgage loan originator that specializes in market sectors such as cannabis-related operations and alternative loans related to the residential marketplace. The company addresses the needs of both traditional and non-traditional loans consumers and businesses, drawing on the strengths it has cultivated through skilled staffing, the organization of a supportive network of independent brokers and loan officers, (https://ibn.fm/8vTSQ).

REZYFi’s operational model specifically sustains cannabis operators where licensed businesses are legally qualified by their state governments, but which are struggling to do business because national drug laws regulated by the federal government create barriers. Banks insured by the federal government have been less likely to take loan risks with client operations not recognized by the federal government, so REZYFi fills a critical marketplace need.

Cannabis operations have seen market booms during the past decade based largely on their state-legal status and their attempts to provide healthful and accessible alternatives to the prescription drug industry. California is one of the leading cannabis-legal states, and one of the largest economies in the world.

REZYFi provides senior loan and project financings to state-legal cannabis businesses and to residential projects that may be related to cannabis businesses. The loans are secured by real estate and other assets of the borrowers “to the extent permitted by applicable laws and regulations governing such borrowers,” according to REZYFi’s website.

For more information, visit the company’s website at www.REZYFi.com.

NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• For some EV owners, charging may cost more than filling up, highlighting the need for enhancing EV efficiency – a metric that relies heavily on the productivity of their complex powertrain system
• Performance of powertrain components directly affects cost, driving range, charge time, and overall driving experience; as a result, inverter technology could determine the speed and success of EV adoption
• Hillcrest’s proprietary ZVS inverter technology is designed to bring benefits for both OEMs in terms of potential for significant savings in the construction of the vehicles, and for the end user

EV manufacturers may need to step up their game as, in today’s economic environment with rising electricity prices, drivers will want to ensure more confidence if they are to choose between an electric car and its conventional counterpart. With a higher purchase price relative to their combustion-engine equivalent, the recent jump in electricity rates could tip the scale for some drivers. That is where innovative solutions like Hillcrest Energy Technologies (CSE: HEAT) (OTCQB: HLRTF) ZVS inverter can help EVs become more efficient and work smarter, not harder.

For some drivers, the lure of EVs has been on a downward slope once the recent energy price volatility entered the equation. Electricity rates in some parts of the country have leaped 30% since last summer, while gasoline prices have decreased below their peak in mid-2022 (https://ibn.fm/GwGgx). Consequently, for a large portion of the country, EVs are not much cheaper to drive compared to conventional cars, and as a result, they may start looking less attractive. In addition, there are other concerns that potential EV buyers often face when deciding about the purchase, such as how far a car can go on one charge and how long it takes to recharge it. If costs and efficiency are two major pain points of the modern EV industry, then Hillcrest appears to be focusing its engineering efforts to solve for both.

The powertrain – a system consisting of batteries, traction inverters, onboard charger, and electric motors – lies at the core of every EV. The efficiency of the powertrain components is crucial since it directly affects costs, driving range, charge time, and general driving performance. As such, it could determine the speed and success of EV adoption. This puts inverters into the spotlight since an efficient power inverter is a critical powertrain component for making EVs more efficient, cost-effective, and attractive to the modern consumer.

That is where Hillcrest aims to step in with its proprietary Zero Voltage Switching (“ZVS”) traction inverter which is designed to set a new standard of performance and efficiency for modern power conversion technologies. The company has recently completed the first commercial prototype of this innovative solution, which is said to be lighter, faster, and more efficient compared to traditional inverters.

Today’s vehicles mainly use conventional inverters running on 400-volt systems (https://ibn.fm/u56ZS), but Hillcrest is confident that the future will be in high-voltage inverters (800/900-volt) with silicon carbide (“SiC”) devices as manufacturers seek to lower long-term system costs in their bid to stay competitive. Its ZVS inverter is believed to enable EV manufacturers to utilize the advantages of the promising silicon carbide up to its limit (https://ibn.fm/uxsq3).

However, the benefits of ZVS don’t seem to stop here, as Hillcrest is optimistic that its innovative technology has many potential values, including the cost control potential. The company believes that its inverter will cost as much or even less than inverters currently available in the market. Still, unlike them, Hillcrest’s ZVS would offer far greater capabilities in terms of efficiency. In a recent investor presentation, the company cited cost savings of $700 per vehicle when using its ZVS inverter. This means that for 100,000 cars in any given model manufactured over a year, OEMs could save $70 million with a bonus of increased benefits for the end user, such as increased range, more efficient batteries, and more.

The list of benefits does not seem to stop here either. For example, OEMs are on the constant lookout for new technologies that can expand the abilities of the batteries, and Hillcrest appears confident that its technology can assist in making battery technology more efficient. Instead of focusing on increasing battery size – already the most expensive EV component and one that adds more weight to the vehicle – the new paradigm concentrates on developing more efficient inverters to make EVs’ powertrain work smarter, not harder. According to the company, a 1% efficiency gains achieved by deploying its inverter can reduce batteries needed by as much as 2%. Payback of these small relative savings can be substantial at the system level.

For more information, visit the company’s website at www.HillcrestEnergy.tech.

NOTE TO INVESTORS: The latest news and updates relating to HLRTF are available in the company’s newsroom at https://ibn.fm/HLRTF